PRESIDENT Trump has nominated Susan Monarez for the Director of the US Centers for Disease Control (CDC). This has sent shockwaves through the Make America Healthy Again (MAHA) community, as they were expecting a covid-era celebrity to take up the reins.
While I was preparing this essay, out of the blue Secretary Robert F Kennedy Jr called me to discuss the nomination of Monarez, so I have first-hand knowledge of the situation. Kennedy confided in me that he strongly supports her.
He describes her as an administrative dynamo who is doing an excellent job as acting CDC director and has been working closely with Elon Musk’s Department of Government Efficiency. For example, there were CDC employees who were obstructing access to important data and key VAERS information. Director Monarez acted promptly to remove these individuals or otherwise obtain access to the necessary data. She did so quickly and efficiently.
No surprise, there is a lot of resistance to change at the CDC, and Monarez is overcoming all obstacles in a prompt and methodical manner. I am shocked, shocked, that there is so much resistance to oversight and reform (sarcasm).
In any case, don’t judge a book by its cover. If the MAHA agenda is to succeed, it will need people like Monarez to lead in key administrative positions. That is, it will require more than popular influencers. It needs people with years of high-level security clearance experience who understand the bureaucracy and how to navigate the rules and regulations so they do not get bogged down in the courts.
The energetic Dr Monarez may be just what the doctor (or perhaps surgeon would be a better metaphor) ordered for treating a very sick CDC.
Let’s just focus on the facts and her CV for a moment. You can make your own assessment and draw your own conclusions from there.
Monarez obtained her PhD at the University of Wisconsin-Madison, where her research focused on infectious disease technologies, particularly those affecting low- and middle-income countries. She did a postdoc at Stanford University School of Medicine, focusing on infectious disease research.
Despite this research background, PubMed lists only one publication under her name. So she is an administrator, not a researcher. Given her years in government, management is clearly what she excels at.
Monarez was a Fellow at the American Association for the Advancement of Science. She held roles in the Office of Science and Technology Policy and the US National Security Council, where her work included initiatives to combat antimicrobial resistance, expand wearable technology for health monitoring, and improve pandemic preparedness efforts (that would include biodefense). She worked in the Obama, Trump 1.0 and Biden White Houses. During Trump’s first term, she held health technology and biosecurity roles, including positions at the Department of Homeland Security and the White House Office of Science and Technology Policy. So she was already known to the Trump Chief of Staff team of Susie Wiles.
At the US Department of Homeland Security, Monarez served as Deputy Assistant Secretary for Strategy and Data Analytics, where she oversaw the research portfolios for the Homeland Security Advanced Research Projects Agency (HSARPA) and the Biomedical Advanced Research and Development Authority (BARDA). More spooky stuff.
In January 2023, Monarez was appointed Deputy Director of the Advanced Research Projects Agency for Health (ARPA-H), where she led initiatives to apply artificial intelligence and machine learning to enhance health outcomes. Under her direction, the ARPA-H program included research on healthcare accessibility and affordability, expanding mental health interventions, combating the opioid epidemic in the United States, and maternal health ‘disparities’. Much of her research has been focused on DEI-related research and health outcomes. However, I believe it is likely her work with artificial intelligence-related solutions applied to public health that has propelled her through the ranks.
Monarez became Acting Director of the Centers for Disease Control and Prevention (CDC) and Acting Administrator of the Agency for Toxic Substances and Disease Registry on January 23, 2025, after being named as the agency’s Principal Deputy Director. She was nominated on March 24, 2025, to be the new CDC director.
Will she survive the nomination process?
I predict that she will garner bipartisan, overwhelming support from the Senate and her nomination will be smooth sailing. Remember, she first worked for Obama and Biden, so the Democrats and the administrative state love her. There is a lot of speculation that she has strong ties to intelligence, and she worked in biodefense, so the Warhawks will adore her.
She was selected to head the CDC because of her work with AI. The use of AI applied to VAERS and the Morbidity and Mortality Weekly Report (MMWR) will be critical in overhauling the adverse events reporting system. I speculate that Robert Kennedy Jr went along because she has the skillset to apply a team of AI experts to MMWR and VAERS and is already working with DOGE. The recent cabinet meeting most likely included thoughts on her nomination. This is a candidate that Musk would support.
Given her progress and achievements to date as acting CDC director I can see why Kennedy would be enthusiastic about this appointment. He gave her a two-month try-out and she passed. Remember always that the goal is getting the job done, not just rewarding people for having been right in the past.
Countless agency heads have come and gone in past administrations and they have been predictably eaten alive by systems they do not understand. This is what Washington has always counted on: just wait it out and the bureaucracy wins every time.
The Trump administration and RFK Jr have a different plan in mind. As with Kash Patel at the FBI, as with the Office of Management and Budget (OMB) and many other agencies, this administration favours people with real experience and a determination to get the job done.
This article appeared in Brownstone Institute on March 27, 2025, and is republished by kind permission.
